Barbash G I, Modan M, Goldbourt U, White H D, Van de Werf F
Sheba Medical Center, Tel Hashomer, Israel.
J Am Coll Cardiol. 1993 Feb;21(2):281-6. doi: 10.1016/0735-1097(93)90664-m.
This study was designed to examine the variation in mortality rates among countries participating in the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Despite uniform inclusion and exclusion criteria and protocol in this trial, 30-day mortality rates (irrespective of treatment allocation) ranged from 4.2% to 14.8% among the participating countries.
With use of the risk factors identified by a multi-variate logistic model, the total study group was classified into deciles on the basis of each patient's risk profile and individual probability of dying within 30 days. Expected mortality rates were then calculated and compared with actual mortality for each decile of the total study group, as well as for patients from each country.
Independent risk factors for mortality were older age (odds ratio 1.97 for each 10-year increment), systolic hypotension (blood pressure < 95 mm Hg) at entry (odds ratio 3.7), Killip class > 1 at entry (odds ratio 3.5), history of antecedent angina (odds ratio 1.23 to 1.49), history of diabetes mellitus (odds ratio 1.64), previous infarction (odds ratio 1.23) and history of never smoking (odds ratio 1.37). The overall mortality rate among the 1,612 patients in risk deciles 9 and 10 was 26%; for the 1,606 patients in deciles 1 and 2 it was 1.2%, with a sensitivity of 58.6% and a specificity of 83.7%. The logistic model closely predicted and explained the different mortality rates for most countries (the differences between expected and actual mortality were nonsignificant). However, in the total study group, the difference between the expected and actual mortality was significant (p < 0.001). This difference was mainly ascribed to the two countries with the highest and lowest mortality rates. When the patients from these two countries were excluded from the analysis, the overall difference became nonsignificant.
These findings suggest that the recognized risk factors associated with increased case fatality in acute myocardial infarction account only in part for mortality differences across or within populations.
本研究旨在调查参与国际组织型纤溶酶原激活剂/链激酶死亡率试验的各国死亡率差异。
尽管该试验有统一的纳入和排除标准及方案,但参与国之间30天死亡率(无论治疗分配情况)在4.2%至14.8%之间。
利用多变量逻辑模型确定的风险因素,根据每位患者的风险概况和30天内死亡的个体概率,将整个研究组分为十分位数。然后计算预期死亡率,并与整个研究组每个十分位数以及每个国家患者的实际死亡率进行比较。
死亡的独立风险因素为年龄较大(每增加10岁比值比为1.97)、入院时收缩期低血压(血压<95mmHg)(比值比为3.7)、入院时Killip分级>1(比值比为3.5)、既往心绞痛病史(比值比为1.23至1.49)、糖尿病病史(比值比为1.64)、既往梗死病史(比值比为1.23)和从不吸烟史(比值比为1.37)。风险十分位数9和10中的1612例患者的总体死亡率为26%;十分位数1和2中的1606例患者为1.2%,敏感性为58.6%,特异性为83.7%。逻辑模型密切预测并解释了大多数国家不同的死亡率(预期死亡率与实际死亡率之间的差异无统计学意义)。然而,在整个研究组中,预期死亡率与实际死亡率之间的差异有统计学意义(p<0.001)。这种差异主要归因于死亡率最高和最低的两个国家。当将这两个国家的患者排除在分析之外时,总体差异变得无统计学意义。
这些发现表明,公认的与急性心肌梗死病死率增加相关的风险因素仅部分解释了不同人群之间或人群内部的死亡率差异。